At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 11, 2026 at 08:00 ET
Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. In the BCMA-naïve recommended dose expansion cohort (n=12), results showed a 92% ORR, 83% CR/≥CR rate, 91% MRD negativity, and 50% of patients sustaining ≥CR at 15 months, with a manageable safety profile. These data will be presented at EHA on June 14, 2026, and initial dose expansion data in both BCMA-naïve and BCMA-exposed patients are expected in H2 2026.
- Single dose of CB-011 at the 450M cell RDE produced 92% ORR, 83% CR/≥CR rate, 91% MRD negativity in BCMA-naïve patients (n=12).
- 50% of patients in the BCMA-naïve RDE cohort maintained ≥CR at 15 months; median follow-up 17.7 months.
- A case study of a patient who had failed approved autologous CAR-T (cilta-cel) achieved CR by day 28 with CB-011.
- Safety profile was manageable with no GvHD, parkinsonism, or cranial nerve palsies; one (8%) ≥Gr 3 CRS, no ≥Gr 3 ICANS at RDE.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access